The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma

The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab-paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Palacio, Sofia, Hosein, Peter J., Reis, Isildinha, Akunyili, Ikechukwu I., Ernani, Vinicius, Pollack, Terri, Macintyre, Jessica, Restrepo, Maria H., Merchan, Jaime R., Rocha Lima, Caio M.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2018
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848048/
https://ncbi.nlm.nih.gov/pubmed/29564179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2017.10.12
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados